While DNA damage response pathways are well characterized in cancer cells, much less is known about their status in normal cells. These pathways protect tumour cells from DNA damage and replication stress and consequently present potential therapeutic targets. Here we characterize the response of human telomerase reverse transcriptase (hTERT)-immortalized normal human urothelial (NHU) and bladder cancer cell lines to agents that disrupt the DNA damage response. Effects of replication and DNA damage response inhibitors on cell cycle progression, checkpoint induction and apoptosis were analysed in hTERT-NHU and bladder cancer cell lines. The primary signalling cascade responding to replication stress in malignant cells (ataxia telangiectasiamutated (ATM) and Rad3-related-checkpoint kinase 1 (ATR-CHK1)) is not activated in hTERT-NHU cells after treatment with a replication inhibitor and these cells do not depend upon CHK1 for protection from apoptosis during replication stress. Instead, ATM signalling is rapidly activated under these conditions. Intriguingly, an ATM inhibitor suppressed S-phase checkpoint activation after exposure to replication inhibitors and stopped entry of cells into S-phase indicating G1 checkpoint activation. Consistent with this, hTERT-NHU cells treated with the ATM inhibitor showed increased levels of cyclin-dependent kinase inhibitor p19
INTRODUCTION
Loss of cell cycle control enhances the accumulation of genetic changes that lead to transformation of normal cells to cancer cells, and the generation of invasive, metastatic tumours. In response to DNA damage or replication stress, checkpoints arrest cell cycle progression to provide time for DNA repair. Activated checkpoints may also trigger cell death in response to some types of DNA damage, 1,2 although they have also been shown to protect tumour cells from apoptosis. [3] [4] [5] In eukaryotic cells, there are two highly conserved signalling cascades that are largely channelled through two members of the phosphatidylinositol 3-kinase-like family of kinases, ataxia telangiectasia-mutated (ATM) and ATM and Rad3-related (ATR). 6 Upon activation by DNA damage or replication stress, these kinases phosphorylate a number of target proteins to ensure DNA integrity, including the key protein kinases, checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2).
7 CHK1/CHK2 are structurally unrelated serine/threonine protein kinases that functionally overlap in the checkpoint signalling cascade and are activated in response to many different stimuli. 7 In general, the ATM-CHK2 signal-transduction pathway responds to DNA double-strand breaks or ends while the ATR-CHK1 pathway is mainly activated in response to the accumulation of single-stranded DNA at stalled DNA replication forks. CHK1 is an unstable protein, whose expression is restricted to S and G 2 phases. 8 In contrast, CHK2 is stable and expressed throughout the cell cycle, which reflects the role of the ATM-CHK2 signalling cascade in the repair of DNA lesions arising throughout the cell cycle. 9 Recently, there has been growing interest in the use of CHK1 inhibitors in cancer therapy. [10] [11] [12] [13] CHK1 kinase regulates cell cycle progression from S to M phase following disruption of DNA replication or some types of DNA damage and has also been reported to have a role in the S phase in undisturbed cells. [14] [15] [16] CHK1 has a vital role in mammalian development and viability and CHK1 knockout causes embryonic lethality in mice. 17, 18 Cells cultured from early embryos of such strains fail to survive and show extensive apoptosis. 17 Although CHK1 knockout or depletion is not invariably lethal, many cell types depleted of CHK1 grow slowly (with a particularly slower progression through the S phase) and show increased levels of spontaneous apoptosis. 15, 19 However, when DNA replication is disrupted, small interfering RNA-mediated CHK1 depletion or small-molecule inhibition of CHK1 can trigger cell death in many cell types. 3, [20] [21] [22] These findings indicate that CHK1 protects cells from apoptosis caused by DNA replication stress. However, the principal cell models used for CHK1 studies have either been cancer cell lines or immortalized fibroblasts. Considering that most tumours have an epithelial origin, it is important to understand the status of these pathways in epithelial cells to more effectively target therapies to developing tumours. Here we investigated the response of hTERT-immortalized normal human urolthelial (NHU) cells to DNA replication stress. In contrast to bladder cancer cells, the ATM-CHK2 protein kinase cascade responds earliest to DNA replication stress in hTERT-NHU cells, whereas CHK1 shows an aberrant pattern of phosphorylation that lags behind the ATM response. Our data further indicate that ATM inhibition triggers a G1 checkpoint in hTERT-NHU cells that prevents S-phase entry. While neither ATM nor CHK1 inhibitors trigger cell death in response to DNA replication stress in hTERT-NHU cells, both induce apoptosis in bladder cancer cells.
RESULTS
CHK1 inhibition slows S-phase progression in response to DNA replication stress in hTERT-NHU cells but does not trigger apoptosis To determine the response of non-malignant epithelial cells to DNA replication stress, hTERT-NHU cells were treated with thymidine for 24 or 48 h in the presence or absence of the CHK1 inhibitor Gö6976. Cells were harvested and analysed for DNA content by flow cytometry. Cells treated with the CHK1 inhibitor alone for 24 or 48 h showed no significant change in cell cycle distribution relative to control (Figure 1a ). Cultures treated with thymidine showed an accumulation of cells with a DNA content characteristic of slowed progression through the S phase. Following treatment with a combination of thymidine and Gö6976, cells accumulated in the S phase at 24 h similar to those treated with thymidine alone (Figure 1a) . However, after 48 h, hTERT-NHU cells treated with the combination failed to progress further through the S phase, whereas the cells treated with thymidine alone progressed slowly through the S phase and accumulated in the G 2 phase. Notably, few hTERT-NHU cells treated with the combination showed a sub-G 1 DNA content characteristic of apoptotic cells. Additionally, hTERT-NHU cells treated with another replication inhibitor (hydroxyurea) in the presence or absence of the CHK1 inhibitor arrested in the S phase without significant induction of apoptosis and cells treated with a second CHK1 inhibitor showed similar responses (Supplementary Figures S1A and B) . Primary human epithelial cells were also tested for their response to Gö6976 and or thymidine. Similar to the hTERT-immortalized cells, these cells accumulated in the S phase in response to thymidine or thymidine and Gö6976, but there was no increase in the fraction of cells with a sub-G1 DNA content (Supplementary Figure S2) . CHK1 inhibitor triggers apoptosis in malignant urothelial cells in the presence or absence of replication inhibitors Treatment of bladder cancer cell lines (TCC-sup and EJ) with thymidine and Gö6976 produced very different effects on cell cycle distribution. Treatment of TCC-sup cells with Gö6976 or thymidine slowed the S-phase transition, whereas a 24 or 48 h cotreatment with the two inhibitors increased levels of cells with a sub-G 1 DNA content relative to cells treated with thymidine alone (Figure 1b) . Strikingly, EJ cells showed a robust apoptotic response to Gö6976 alone after only 24 h with no accumulation in the S-phase, whereas exposure to the combination of the two agents increased the level of cells with a sub-G1 DNA content still further (Figure 1c ). The increase in the sub-G1 population in cultures treated with Gö6976 was accompanied by an increase in the level of activated-caspase-3 in EJ cells (Figure 1d ). In contrast, activated caspase-3 was not detected in Gö6976-treated hTERT-NHU cells in the presence or absence of replication inhibitor.
We further examined the effect of Gö6976 on the response to the deoxycytidine analog gemcitabine, which is widely used in the treatment of advanced bladder cancer. Cells were treated with 12.5 nM gemcitabine in the presence or absence of a 24 h preincubation with Gö6976. Consistent with the response triggered by thymidine, significant cell death was induced by a 24 h cotreatment with gemcitabine and Gö6976 in TCC-sup and EJ, but not in hTERT-NHU cells (Figures 2a-c) . Taken together, these results show that the combination of DNA replication stress agent and CHK1 inhibition produces a strong commitment to apoptosis in bladder cancer lines but not in hTERT-immortalized NHU cells. Thus, a DNA replication stress agent like gemcitabine is selectively able to kill malignant but not normal urothelial cells after CHK1 inhibition.
ATM but not CHK1 is activated early by DNA replication stress in hTERT-NHU cells In response to DNA damage or replication defects, CHK1 is rapidly phosphorylated at Ser317 and Ser345 in a wide range of cells, whereas an autophosphorylation site (Ser296) within the C-terminal regulatory domain 23 is phosphorylated in the absence of replication stress. 24 Both Ser317 and Ser345 are critical for CHK1 function as mutations (S317A or S345A) that eliminate phosphorylation at these sites suppress checkpoint induction and reduce viability. [24] [25] [26] To determine whether these regulatory CHK1 modifications occur in hTERT-NHU cells exposed to replication inhibitors, cultures were treated with thymidine in the presence or absence of Gö6976 for different times and harvested for western blot analysis. CHK1 autophosphorylation at Ser296 was readily apparent in both unstressed and thymidine-treated hTERT-NHU cells. This was suppressed by Gö6976, demonstrating the effectiveness of the kinase inhibition (Figure 3a ). Ser345 phosphorylation of CHK1 could not be detected even after a 24 h thymidine treatment, whereas CHK1 pSer317 was transiently phosphorylated after an 8 h treatment. Interestingly, ATM was autophosphorylated (at Ser1981) by 2 h after thymidine exposure. Downstream phosphorylation targets of activated ATM (pThr68 CHK2 and pSer15 p53) were also detected in hTERT-NHU cells following thymidine treatment. These events were independent of CHK1 activation as they were not affected by CHK1 inhibition. Total levels of some of the signalling proteins were also affected in response to treatment. P53 was stabilized and phosphorylated, whereas the level of CHK1 strikingly decreased in cells treated with the CHK1 inhibitor in the presence or absence of thymidine ( Figure 3a) .
In striking contrast, EJ bladder cancer cells show phosphorylation of CHK1 at Ser345 and Ser317 within 2 h of thymidine treatment ( Figure 3b ). These events are enhanced when tumour cells are cotreated with CHK1 inhibitor. Autophosphorylation of ATM lags in EJ cells, weakly increasing 12 h after thymidine treatment in line with an increase in total ATM. ATM autophosphorylation appears slightly increased in EJ cells treated with thymidine in combination with the CHK1 inhibitor accompanied by increased levels of ATM.
The replication protein A 2 (RPA2) subunit of the RPA complex and histone H2AX are also phosphorylated in response to disruption of DNA replication 14, 27 and these events are amplified in tumour cell lines treated with CHK1 inhibitors or small interfering RNA (Figure 3c) . 28, 29 pSer139 H2AX (γ-H2AX) was only weakly detected in hTERT-NHU cells treated with thymidine alone, whereas both RPA phosphorylation and γ-H2AX were detected at later times after treatment with the combination of Gö6976 and thymidine (Figures 3b and c) . Interestingly, RPA was phosphorylated at Ser4/Ser8 but not Ser33 in these cells ( Figure 3c ). As it has been shown that Ser33 is phosphorylated by ATR under such conditions, 30 ,31 the absence of Ser33 phosphorylation further indicates that ATR-CHK1 signalling is suppressed in hTERT-NHU cells exposed to CHK1 and replication inhibitors. As in other cell types, hTERT-NHU cells cotreated with CHK1 inhibitor and thymidine showed enhanced formation of γ-H2AX foci relative to cells treated for 24 h with thymidine or Gö6976 alone ( Figure 3d ). However, the γ-H2AX foci were more distinct and localized relative to those found in tumour cells such as HCT116 and the pan-nuclear γ-H2AX staining found in tumour cells under these conditions 29 was not evident in hTERT-NHU. Taken together, these data suggest that hTERT-NHU cells have a distinctively different pattern of activation of DNA response pathways relative to tumour cell lines consistent with reduced activation of the ATR-CHK1 signalling cascade during DNA replication stress.
hTERT-NHU cells show reduced levels of RAD51 foci in response to replication inhibition When DNA replication is arrested, a number of proteins are recruited to stalled forks to resolve blocking lesions and restart replication. Among these is the homologous recombination repair protein RAD51. During DNA replication stress, RAD51 forms foci at stalled forks and this response is strongly dependent on CHK1. 32 Given that our evidence indicated that CHK1 activation was suppressed in hTERT-NHU cells following treatment with thymidine, we next determined whether this affected the formation of RAD51 foci. hTERT-NHU cells grown in the presence or absence of replication inhibitor for 24 h were fixed and stained for RAD51. HCT116 colon cancer cells that are known to form RAD51 foci in response to replication stress were also analysed for foci after such treatment. Over 90% of HCT116 cells treated with thymidine showed 410 RAD51 foci, whereas only~25% of hTERT-NHU cells showed a similar response (Figure 4 ). In addition, the foci formed in the hTERT-NHU cells were less intense than those arising in HCT116. The foci formed in hTERT-NHU cells were sensitive to Gö6976, suggesting that there was a low level of CHK1 activation in some cells that was able to trigger formation of RAD51 foci.
Reduction of CHK1 protein levels is accompanied by lower transcript levels Following phosphorylation of CHK1 at Ser345 in response to DNA replication stress, CHK1 is ubiquitinated by the Skp1-Cul1-Fxb6 E3 ligase targeting it for proteasome-mediated degradation. 33 Even though there was no phosphorylation of CHK1 Ser345 in hTERT-NHU cells treated with thymidine, we determined whether the lower level of CHK1 in such cells was the result of increased degradation of CHK1. Cells treated with Gö6976 and thymidine were exposed to the proteasome inhibitor MG-132. Unlike the response of tumour cells, 34 CHK1 levels were not restored by treatment with MG-132 (Figure 5a ). However, quantitative realtime (qPCR) analysis showed that Gö6976-treated hTERT-NHU cells had a more than twofold lower level of CHK1 transcripts (Figure 5b) . Thus, the decrease in CHK1 found after treatment with the CHK1 inhibitor appears to be the result of decreased transcription.
ATM kinase activity is required for G 1 -S phase transition in hTERT-NHU cells but not S-phase progression Given the relatively early activation of ATM following thymidine treatment in the presence or absence of Chk1 inhibitor, we next determined the effect of ATM inhibition on immortalized normal urothelial cells during DNA replication stress. hTERT-NHU cells were pretreated with 10 μM of the highly specific ATM inhibitor KU55933 35 for 2 h and then incubated with or without thymidine or gemcitabine for 24 h. Cells were harvested for cell cycle analysis by flow cytometry. After KU55933 treatment, the fraction of cells in the S phase was significantly reduced in the presence or absence of thymidine or gemcitabine relative to untreated cultures (Figures 6a and b) . Primary NHU cells showed a similar reduction in the fraction of cells in the S phase after treatment with KU55933 in the presence or absence of thymidine (Supplementary Figure S2) . Additionally, a second ATM inhibitor KU60019 reduced the fraction of hTERT-NHU cells in the S phase (Supplementary Figure S3) .
To determine whether the effect of the ATM inhibitor was limited to cells entering the S-phase, hTERT-NHU cells treated with KU55933 were exposed to the mitotic inhibitor nocodazole to trap cycling cells entering the G 2 /M phase. The combination of ATM inhibitor and nocodazole reduced the level of S-phase cells and increased the number in the G 2 /M phase relative to untreated cells (Supplementary Figure S4) . This appeared to be the result of the transition of the cells already in the S-phase into the G 2 /M phase where they were trapped by nocodazole treatment. However, no new cells appeared to enter the S phase. Consistent with this, the fraction of cells incorporating bromodeoxyuridine (BrdU) fell to very low levels by 24 h after treatment with KU55933 (Figure 6c) . Nevertheless, the effects of KU55933 were reversible as cells reenter the S phase and incorporate BrdU by 24 h after removal of the inhibitor (Supplementary Figure S5) .
hTERT-NHU cells were also pulsed with BrdU for 2 h before the addition of ATM inhibitor to follow the fate of cells already in the S phase. Cells were then harvested 24 h after addition of KU55933 and analysed for both DNA content and BrdU incorporation. In the presence or absence of the ATM inhibitor, labelled cells progressed through the S phase and by 24 h were present in both the G2/M and G1 phases (Supplementary Figure S6) , suggesting that the ATM inhibitor had little effect on S-or G2/M-phase transition. Taken together, our data suggest that ATM is required for the entry of hTERT-NHU cells into the S phase but not progression through the S or G2/M phase.
Western blot analysis of extracts prepared from hTERT-NHU cultures showed that the ATM inhibitor suppressed the autophosphorylation of ATM after thymidine treatment, confirming the effectiveness of the inhibitor (Figure 7a ). Phosphorylated forms of the checkpoint kinases and p53 decreased under these conditions relative to cells treated with thymidine alone. Phosphorylated forms of RPA or γ-H2AX were not detected in cells treated with the combination of ATM inhibitor and thymidine (Figures 7a and b) . In addition, there was no further increase in the fraction of cells forming γ-H2AX foci following treatment with the two agents relative to cells treated with thymidine or KU55933 alone (Figure 7c ), whereas the ATM inhibitor significantly reduced the fraction of cells forming RAD51 foci after thymidine treatment (Figure 4) . These results are consistent with our conclusion that hTERT-NHU cells fail to enter the S phase after treatment with the ATM inhibitor.
EJ bladder cancer cells show enhanced apoptosis after treatment with the ATM inhibitor and thymidine When EJ cancer cells were treated with KU55933 alone, the fraction of S-phase cells significantly increased relative to untreated cultures, but few cells with a sub-G1 DNA content were Figure 3 . Western blot analysis of DNA damage response proteins in hTERT-NHU or EJ cells treated with thymidine in the presence or absence of CHK1 inhibitor. hTERT-NHU (a) or EJ bladder cancer (b) cells were exposed to 1 mM thymidine for 0-24 h in the presence or absence of 1 μM Gö6976 before harvest and preparation of cell-free extracts. Cells treated with Gö6976 were preincubated with the inhibitor for 2 h before the addition of thymidine, those treated with the CHK1 inhibitor alone (0 h thymidine) were exposed for 24 h. Western blots prepared from these extracts were analysed for the indicated damage response proteins. β-Actin levels are presented as loading controls. detected (Figure 6d) . Upon exposure to KU55933 and thymidine, there was a marked increase in the fraction of cells with a sub-G1 DNA content accompanied by a decreased level of S-and G2/Mphase cells and activation of caspase-3 (Figures 6d and e) compared with cells treated with thymidine alone. Thus, in striking contrast to the hTERT-NHU cells, ATM inhibition slows S-phase transition in EJ cells and strongly commits these cells to apoptosis during DNA replication stress.
ATM inhibition triggers a G1 checkpoint hTERT-NHU cells To determine whether the failure of hTERT-NHU cells to enter the S phase was the result of an induction of a G1 checkpoint, proteins regulating S-phase entry were analysed in cells treated with KU55933. Levels of the cyclin-dependent kinase p16
INK4a were not altered following exposure to KU55933 in the presence or absence of thymidine ( Figure 7d) ; however, there was a 1.5-to 2-fold increase in the level of another such inhibitor p19 INK4D and the CDK4/6-mediated phosphorylation of RB that is normally triggered in cells entering the S phase was reduced in cells treated with KU55933. Additionally, cyclin D1 and CDK4 levels were lower in cells treated with the ATM inhibitor characteristic of cells arrested in G1. 36 There was no increase in the level of another CDK inhibitor (CDKN1A) in cells treated with the ATM inhibitor (Figures  7a and d) . Taken together, these results suggest that hTERT-NHU cells fail to enter the S phase after treatment with the ATM inhibitor, as a result of the activation of a G1 checkpoint. DISCUSSION DNA damage response proteins regulate cell cycle progression following DNA damage or replication disruption and many are important for optimal growth of undisturbed cells. Work from many laboratories has shown that CHK1 regulates S-phase progression in tumour cells and protects them from apoptosis in response to DNA replication stress. [3] [4] [5] 15 However, how these proteins function in 'normal' epithelial cells is less clear. Here, we report that CHK1 is necessary for efficient progression of primary and hTERT-immortalized bladder epithelial cells through the S phase during DNA replication stress but is not required to protect such cells from apoptosis. In contrast to the response reported for many types of tumour cells, our data indicate that CHK1 is not fully activated in hTERT-NHU cells after treatment with a replication inhibitor. CHK1 is largely activated as a result of single-stranded DNA formation that occurs when DNA polymerase and helicase complexes become uncoupled following replication inhibition. 37 This single-stranded DNA is rapidly coated by RPA that, in turn, recruits ATR through the ATR-interacting protein. 38 The formation of this complex drives the activation of CHK1 through phosphorylation at Ser345 and Ser317. 18, 39 We show that this critical phosphorylation of CHK1 (on Ser345) in response to thymidine treatment does not occur in hTERT-NHU cells. CHK1 S345A mutations show loss of viability characterized by induction of mitotic catastrophe, apoptosis and/or impaired cell cycle checkpoints in many types of cells. [24] [25] [26] Thus, the failure to phosphorylate this site would be likely to curtail severely the CHK1-mediated damage response.
Our data suggest that this lack of Ser345 phosphorylation is due to the inability of hTERT-NHU cells to activate ATR in response to replication stress. RPA2 has a distinctive pattern of phosphorylation in tumour cell lines in response to replication and CHK1 inhibitors. 30, 40 There is a general agreement that Ser33 is a phosphorylation target for activated ATR, 30, 31 whereas Ser4/8 phosphorylation may be produced through ATM or DNAdependent protein kinase activity. 40 Ser4/8 phosphorylation of RPA is usually found only in the most hyperphosphorylated forms of RPA2 during DNA replication stress and evidence suggests that it occurs after phosphorylation of Ser33 by ATR. 30 Thus, the lack of Ser33 phosphorylation in hTERT-NHU cells treated with thymidine in the presence or absence of CHK1 inhibitors combined with the Ser4/8 phosphorylation suggests that the ATR pathway is not activated in these cells and that ATM or DNA-dependent protein kinase signalling provides the initial response to replication fork stress in the immortalized epithelial cells. Interestingly, the ATM inhibitor suppressed Ser4/8 phosphorylation under these conditions; however, this may simply be due to a failure of cells treated with the ATM inhibitor to enter the S phase. Nevertheless, our data show that ATM is activated as an early event in hTERT-NHU cells treated with thymidine. While ATM activation has largely been associated with double-strand break formation, other pathways that resolve stalled forks could generate the DNA ends that trigger ATM activation. For example, stressed forks in such cells may be more likely to undergo regression to generate a 'chicken foot structure' with a DNA end or transient breaks generated during the resolution of stalled forks could potentially activate ATM. 41, 42 As phosphorylation of CHK1 at Ser345 is required for the Fbx6-mediated degradation of CHK1, 33 the absence of this phosphorylation in hTERT-NHU cells is likely to contribute to the stability of CHK1 seen in these cells during thymidine treatment. In contrast, treatment with Gö6976 destabilized CHK1 in the presence or absence of thymidine. A proteasome inhibitor failed to restore CHK1 levels, although qPCR analysis indicated lower levels of CHK1 transcription. This suggests that CHK1 kinase activity is necessary to maintain its own level in hTERT-NHU cells, even in the absence of replication stress. CHK1 associates with chromatin during normal growth, 43 where it phosphorylates histone H3 on residue Thr11 even in the absence of activation. 44 This has been shown to be necessary for the transcription of some regulators of cell cycle progression, 44 although the previous study did not reveal whether the CHK1 kinase regulated its own level.
Intriguingly, while ATM is more rapidly activated in response to DNA replication stress in hTERT-NHU cells, the most obvious effect of ATM inhibition is a block to S-phase entry. Although the role of ATM in the activation of the G1-S checkpoint in response to DNA double-strand breaks is well documented, there are few examples of a requirement for ATM in the G1-S transition in unstressed cells. Notably, ATM is required for the self-renewal of mouse haematopoietic stem cells through its role in regulating oxidative stress. 45 In cells derived from ATM − / − mice, an accumulation of reactive oxygen species activates p16
INK4a
, which in turn inhibits RB phosphorylation and thus entry into the S phase. In hTERT-NHU cells, RB phosphorylation was reduced after treatment with the ATM inhibitor, although p16
INK4a accumulation was not detected and a reactive oxygen species inhibitor did not reverse the G1 block (data not presented). However, levels of the CDK4/6 inhibitor p19 INK4D increased, whereas cyclin D1 and CDK4 levels were reduced under these conditions. These alterations are consistent with a G1 block restricting S-phase entry, 36 although p19 INK4D knockdowns will be necessary to confirm its role in the G1 arrest. Why ATM is necessary for the G1/S-phase transition also requires further investigation. Given that induction of p19 INK4D occurs after exposure of neuroblastoma cells to ultraviolet light to enhance ultraviolet-induced repair and protect cells from apoptosis, 46 it is possible that ATM protects these cells from some sort of endogenous DNA damage (outside of reactive oxygen species). However, as p19 INK4D can also be induced by the hormonal form of vitamin D3 and retinoids to trigger cell cycle arrest, 47 it is possible that ATM regulates some sort of growth signal for the bladder epithelial cells. The ATM requirement for S-phase entry is not evident in bladder cancer lines as these cells accumulate in the S phase after treatment with the ATM inhibitor and commit to apoptosis in the presence of ATM and replication inhibitors. This may be a consequence of disruptions of the control of the G1/S transition caused by alterations of the RB pathway that are commonly found in many types of tumour cells. 48 However, this needs to be critically tested by inactivating the RB pathway in hTERT-NHU cells. Oncogenic transformation of cells increases levels of DNA damage or replication stress making them more dependent on DNA damage response pathways to maintain viability. [49] [50] [51] To cope with this stress, many tumour cell lines show dependence on CHK1 for protection from apoptosis during DNA replication stress and have elevated levels of this protein. 52 Here we show that some bladder cancer cell lines also become dependent on ATM to protect them from death, although this response may be highly tumour cell dependent. While a combination of ATM and replication inhibitors may provide a novel approach to kill specifically bladder cancer cells that does not damage normal epithelia, it is apparent that biomarkers will be required to predict which tumour cells are most likely to respond to such therapies.
MATERIALS AND METHODS

Cell lines and culture
hTERT-NHU cells (gift of Prof Margaret Knowles, University of Leeds, Leeds, UK) were generated by transfection of primary NHU cells derived from urothelial biopsies with an hTERT expression construct. 53 hTERT-NHU cells were maintained in keratinocyte serum-free medium (KSFMc) supplemented with epidermal growth factor, bovine pituitary extract and cholera toxin. EJ and TCC-sup urothelial carcinoma lines (LGC Standards, Teddington, UK) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% non-essential amino acids. Fetal calf serum was dialysed to remove deoxynucleosides that may interfere with the response to replication inhibitors.
Cell cycle analysis
A total of 5 × 10 5 cells were seeded into 6-well culture dishes for 24 h to allow attachment. After treatment, both floating and adherent cells were collected and pelleted together by centrifugation. Harvested cells were processed and stained with propidium iodide for analysis of DNA content as described previously. 3 Cell cycle distribution was analysed by FACScan flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA) with CellQuest software (BD Biosciences). BrdU incorporation was measured by flow cytometry as described previously. 29 Western blot
